Program
jaktinib
Also written as “Jaktinib Hydrochloride Tablets”, “Jaktinib” and “Jaktinib hydrochloride tablets”.
Its studies are mostly in Primary Myelofibrosis · Dermatitis, Atopic · Alopecia Areata · Spondylitis, Ankylosing · COVID-19, led by Suzhou Zelgen Biopharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou Zelgen Biopharmaceuticals | 318 open or running | phase 3since Oct 26, 2020 | Mar 20, 2019 | Feb 2027phase 1 · NCT07565597 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Mar 20, 2019.
- Jul 23, 2021Phase 1 study in Hepatic InsufficiencyNCT04993404 · 24 enrolled · China
- Sep 11, 2021Phase 3 study in Alopecia AreataNCT05051761 · 425 enrolled · China
- Nov 24, 2021Phase 1 study in Healthy Adult Male VolunteersNCT05150717 · 6 enrolled · China
- Feb 11, 2022Phase 3 study in Alopecia AreataNCT05255237 · 315 enrolled · China
- Mar 2, 2022Phase 1 study in Primary MyelofibrosisNCT05279001 · 26 planned · United States
- Aug 25, 2022Phase 3 study in Dermatitis, AtopicNCT05526222 · 443 enrolled · China
- Dec 30, 2022Phase 3 study in Dermatitis, AtopicNCT05676242 · 207 enrolled · China
- Jan 8, 20233 phase 2 studiesNCT05686629, NCT05688839, NCT05702788
- May 6, 20232 phase 3 studies in Spondylitis, AnkylosingNCT05861128, NCT05861102
- Nov 9, 2023Phase 1 study in Primary MyelofibrosisNCT06132243 · 52 enrolled · China
- Dec 20, 2023Phase 1 study in Healthy ParticipantsNCT06193148 · 32 enrolled · China
- Jan 30, 2024Phase 1 study in Healthy VolunteersNCT06246695 · 40 enrolled · China
- Mar 13, 20252 phase 2 studiesNCT06883526, NCT06903377
- Apr 27, 2026Phase 1 study in HealthyNCT07565597 · 64 enrolled · China
Ahead
- Feb 2027Primary completion: phase 1 study in HealthyNCT07565597
- Apr 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06903377
- Apr 2027Primary completion: phase 2 study in LymphomaNCT06883526
TargetBeta
“Jaktinib is a broad-spectrum kinase inhibitor that targets non-receptor tyrosine Janus-associated kinases (JAK1, JAK2, JAK3, and TYK2), as well as FLT3 (FMS-like tyrosine kinase 3) and c-Kit.”study text, by rule · the study
Studies
All 31 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07565597Healthy · China | 1 | Active, not recruiting | Feb 2027 | 64 |
| NCT06903377Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Apr 2027 | 50 |
| NCT06883526Lymphoma · China | 2 | Recruiting | Apr 2027 | 60 |
| NCT06246695Healthy Volunteers · China | 1 | Completed | Jan 12, 2022 | 40 |
| NCT06193148Healthy Participants · China | 1 | Completed | Jun 18, 2024 | 32 |
| NCT06132243Primary Myelofibrosis · China | 1 | Completed | Dec 20, 2023 | 52 |
| NCT05861128Spondylitis, Ankylosing · China | 3 | Completed | Mar 4, 2026 | 207 |
| NCT05861102Spondylitis, Ankylosing · China | 3 | Completed | Jun 9, 2025 | 265 |
| NCT05702788COVID-19 | 2 | Withdrawn | Apr 23, 2024 | 0 |
| NCT05688839Novel COVID-19-Infected Pneumonia · China | 2 | Not yet recruiting | Feb 2025 | 60 |
| NCT05686629Novel COVID-19-Infected Pneumonia · China | 2 | Not yet recruiting | Feb 2025 | 120 |
| NCT05676242Dermatitis, Atopic · China | 3 | Completed | Mar 12, 2026 | 207 |
| NCT05526222Dermatitis, Atopic · China | 3 | Completed | Aug 5, 2025 | 443 |
| NCT05279001Primary Myelofibrosis · United States | 1 | Recruiting | May 31, 2025 | 26 |
| NCT05255237Alopecia Areata · China | 3 | Completed | Jun 28, 2024 | 315 |
| NCT05150717Healthy Adult Male Volunteers · China | 1 | Completed | Jan 30, 2022 | 6 |
| NCT05051761Alopecia Areata · China | 3 | Completed | Dec 27, 2023 | 425 |
| NCT04993404Hepatic Insufficiency · China | 1 | Completed | Sep 19, 2022 | 24 |
| NCT04971551Acute Graft-Versus-Host Disease · China | 2 | Not yet recruiting | Jun 2025 | 60 |
| NCT04866056Myelodysplastic Syndromes · China | 2 | Terminated | Jun 10, 2022 | 1 |
| NCT04851535Primary Myelofibrosis · China | 2 | Completed | Nov 1, 2022 | 34 |
| NCT04612699Moderate-to-Severe Plaque Psoriasis · China | 2 | Completed | Aug 15, 2022 | 123 |
| NCT04617028Primary Myelofibrosis · China | 3 | Completed | Oct 18, 2023 | 105 |
| NCT04539639Dermatitis, Atopic · China | 2 | Completed | May 19, 2022 | 166 |
| NCT04507659Spondylitis, Ankylosing · China | 2 | Completed | Aug 2, 2022 | 108 |
| NCT04445363Alopecia Areata · China | 2 | Active, not recruiting | Dec 1, 2024 | 160 |
| NCT04435392Dermatitis, Atopic · China | 2 | Completed | Sep 8, 2022 | 107 |
| NCT04312594Idiopathic Pulmonary Fibrosis · China | 2 | Completed | Jun 9, 2022 | 91 |
| NCT04217993Primary Myelofibrosis · China | 2 | Completed | Aug 3, 2022 | 51 |
| NCT04034134Alopecia Areata · China | 2 | Completed | Nov 26, 2021 | 111 |
| NCT03886415Primary Myelofibrosis · China | 2 | Completed | Feb 2, 2021 | 118 |
How it is read
Names in the registry
- “Jaktinib Hydrochloride Tablets”, 12 entries
- “Jaktinib”, 11 entries
- “Jaktinib hydrochloride tablets”, 6 entries
- “Jaktinib Hydrochloride Tablet”, 3 entries
- “Gecacitinib Hydrochloride Tablets”, 3 entries
Conditions, from the studies’ own filings
- Primary Myelofibrosis, 6 studies
- Dermatitis, Atopic, 4 studies
- Alopecia Areata, 4 studies
- Spondylitis, Ankylosing, 3 studies
- COVID-19, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.